A Population-based Study of tau Protein and Ubiquitin in Cerebrospinal Fluid in 85-year-olds: Relation to Severity of Dementia and Cerebral Atrophy, but not to the Apolipoprotein E4 Allele
| Autor: | Kaj Blennow, Lars-Arne Andreasson, Bo Palmertz, Ingmar Skoog, Eugeen Vanmechelen, Camilla Hesse, Pia Davidsson |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
Apolipoprotein E medicine.medical_specialty Pathology Apolipoprotein E4 Tau protein tau Proteins Pathology and Forensic Medicine Apolipoproteins E Atrophy Alzheimer Disease Internal medicine mental disorders medicine Humans Dementia Senile plaques Vascular dementia Ubiquitins Alleles Aged Aged 80 and over Cerebral atrophy biology Leukoaraiosis Brain medicine.disease Neuropsychology and Physiological Psychology Endocrinology Case-Control Studies Population Surveillance biology.protein Female Neurology (clinical) Psychology |
| Zdroj: | Neurodegeneration. 4:433-442 |
| ISSN: | 1055-8330 |
| DOI: | 10.1006/neur.1995.0052 |
| Popis: | Alzheimer's disease (AD) is the most common form of dementia, and is characterized by a degeneration of neurones and their synapses, and a higher number of senile plaques (SP) and neurofibrillary tangles (NFT) compared with that found in non-demented individuals of the same age. NFT are composed of a hyperphosphorylated and ubiquitinated form of tau protein. Previous studies have found that in the cerebrospinal fluid (CSF) both tau and ubiquitin are increased in AD. We examined CSF-tau and CSF-ubiquitin in a population based sample of 85-year-olds, 26 demented (11 with probable Alzheimer's disease (AD), 13 with probable vascular dementia (VAD) and 2 with mixed (AD/VAD) type of dementia) and 35 non-demented individuals. CSF-tau was significantly higher both in the probable AD group (254 +/- 113 pg/mL; P0.01), and in the probable VAD group (247 +/- 75 pg/mL; P0.005), than in the non-demented group (171 +/- 78 pg/mL), but did not significantly differ between the probable AD and probable VAD groups. In contrast, CSF-ubiquitin did not significantly differ between the probable AD (100 +/- 24 ng/mL), probable VAD (102 +/- 16 ng/mL), and non-demented (97 +/- 27 ng/mL) groups. CSF-tau increased with increasing severity of dementia (P0.001), though no such relation was found for CSF-ubiquitin. Neither CSF-tau nor CSF-ubiquitin differed between patients with or without the apolipoprotein E E4 isoform. Higher CSF-tau and CSF-ubiquitin levels were also associated with increasing degree of cortical and central brain atrophy as measured by computerized tomography. The relationships between CSF-tau and severity of dementia and to brain atrophy suggest that CSF-tau may be used as a measure of neuronal/axonal degeneration in patients with dementia. We have previously shown a marked increase in both CSF-tau and CSF-ubiquitin in younger patients with AD and VAD. The less pronounced increase in CSF-tau and the lack of difference in CSF-ubiquitin in older patients suggest that the severity of the degenerative process is less in older than in younger demented patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect